Conversion and storage of somatostatin are established before response to secretagogue stimuli in P19 neurons.
In mature neurons, neuropeptides are synthesized via limited proteolysis of propolypeptides by convertases. The bioactive peptides are then stored in secretory granules until they are released extracellularly upon the induction of a fusion between granules and the plasma membrane, in response to secretagogues. We used the mouse P19 embryonic carcinoma cells as a model to determine if the capacities to convert and store neuropeptides and to secrete them in a regulated fashion are established coordinately during neuronal differentiation. We have previously shown that both undifferentiated P19 cells and their neuronal derivatives express the largely distributed furin, PACE4 and PC5 convertases, whereas only neuronal derivatives express the neuroendocrine convertase PC2. In addition, undifferentiated cells displayed furin- rather than PC2-like converting capacities. The present work demonstrates that day 8 P19 neurons mainly convert prosomatostatin (proSS) to somatostatin-14 (SS-14) using HPLC and radioimmunoassay (RIA) analyses, indicating that P19 cells acquire PC2-like converting capacities as a consequence of neuronal differentiation. SS-14 was predominantly intracellular in neuronal cells which were shown to express several granins, markers of granules, by Western blotting. However, cell membrane depolarization with 50 mM K+, a general secretagogue stimulus, evoked the release of SS-14 by day 12, but not by day 8, P19 neurons. The results thus demonstrate that capacities to convert and store neuropeptides can be established before coupling of stimulus-secretion during neuronal differentiation.
Cadet
N
N
Laboratoire de Neuroendocrinologie Développementale, Département de Chimie et de Biochimie, Université du Québec à Montréal, C.P. 8888, Succursale Centre-ville, Montreal, Quebec, Canada.
Paquin
J
J
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000375:Aging / Q000187:drug effects / Q000502:physiology; D000818:Animals; D002273:Carcinogens / Q000494:pharmacology; D002454:Cell Differentiation / Q000502:physiology*; D002490:Central Nervous System / Q000254:growth & development / Q000378:metabolism*; D053379:Chromogranin A; D002864:Chromogranins / Q000378:metabolism; D018507:Gene Expression Regulation, Developmental / Q000502:physiology; D007476:Ionophores / Q000494:pharmacology; D051379:Mice; D014411:Neoplastic Stem Cells; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D010447:Peptide Hydrolases / Q000378:metabolism; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D011189:Potassium Chloride / Q000494:pharmacology; D011498:Protein Precursors / Q000378:metabolism*; D011506:Proteins; D022142:Secretory Vesicles / Q000187:drug effects / Q000378:metabolism*; D013004:Somatostatin / Q000378:metabolism*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
D002273:Carcinogens; D053379:Chromogranin A; D002864:Chromogranins; D007476:Ionophores; D010726:Phosphodiesterase Inhibitors; D011498:Protein Precursors; D011506:Proteins; D013004:Somatostatin; D011189:Potassium Chloride; C028456:prosomatostatin; D010447:Peptide Hydrolases; D013755:Tetradecanoylphorbol Acetate; D015056:1-Methyl-3-isobutylxanthine